NRX Therapeutics: Boral Capital Raises PT to $34, Maintains Buy Rating.

Monday, Mar 16, 2026 3:16 pm ET1min read
NRXP--

NRX Therapeutics: Boral Capital Raises PT to $34, Maintains Buy Rating.

NRX Therapeutics: Boral Capital Raises PT to $34, Maintains Buy Rating.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet